Quantifying Cognitive Decline in Dogs Could Help Humans With Alzheimer’s Disease
For Immediate Release
Researchers have found that a suite of complementary tests can quantify changes in dogs suspected of suffering from cognitive decline. The approach could not only aid owners in managing their elderly canine’s care, but could also serve as a model for evaluating cognitive decline progression in – and treatments for – humans with Alzheimer’s disease.
Canine cognitive dysfunction syndrome (CCDS) is similar to Alzheimer’s disease in humans in that cognitive decline is associated with the development of amyloid plaques as well as cortical atrophy, a progressive degeneration of brain tissue. CCDS is also challenging to diagnose. Traditionally, CCDS is diagnosed based on ruling out any obvious physical conditions and an owner’s answers to a questionnaire.
“One problem with the current approach is that questionnaires only capture a constellation of home behaviors,” says Natasha Olby, the Dr. Kady M. Gjessing and Rahna M. Davidson Distinguished Chair in Gerontology at North Carolina State University and co-senior author of a paper describing the work. “There can be other reasons for what an owner may perceive as cognitive decline – anything from an undiagnosed infection to a brain tumor.”
Olby and co-senior author Margaret Gruen, assistant professor of behavioral medicine at NC State, wanted to determine whether cognitive function could be accurately quantified in dogs.
“Our goal was to bring together multiple tools in order to get a more complete picture of how CCDS presents in dogs,” Gruen says.
To that end, the researchers recruited 39 dogs from 15 breeds. All of them were in the senior and geriatric age range, but in good health overall. A dog is considered “senior” if it is in the last 25% of its expected life span based on breed and size, and geriatric beyond that.
The dogs underwent physical and orthopedic exams, as well as lab work that included a blood test that is a marker of neuronal death. Their owners filled out two commonly used diagnostic questionnaires, and then the dogs participated in a series of cognitive tests designed to assess executive function, memory and attention.
“The approach we took isn’t necessarily designed to be diagnostic; instead, we want to use these tools to be able to identify dogs at an early stage and be able to follow them as the disease progresses, quantifying the changes,” Olby says.
The team found that cognitive and blood test results correlated well with the questionnaire scores, suggesting that a multi-dimensional approach can be used to quantify cognitive decline in aging dogs.
“Being able to diagnose and quantify CCDS in a way that is clinically safe and relevant is a good first step toward being able to work with dogs as a model for Alzheimer’s disease in humans,” Olby says. “Many of the current models of Alzheimers disease – in rodents, for example – are good for understanding physiological changes, but not for testing treatments.”
“Dogs live in our homes and develop naturally occurring disease just like we do,” Gruen says. “These findings show promise for both dogs and humans in terms of improving our understanding of disease progression as well as for potentially testing treatments.”
The work appears in the Journal of Alzheimer’s Disease. NC State postdoctoral fellows Gilad Fefer and Wojciech K. Panek are co-first authors of the work.
Note to editors: An abstract follows.
“Use of Cognitive Testing, Questionnaires, and Plasma Biomarkers to Quantify Cognitive Impairment in an Aging Pet Dog Population”
Authors: Gilad Fefer, Wojciech K. Panek, Michael Z. Khan, Matthew Singer, Hans Westermeyer, Freya M. Mowat, Beth Case, Natasha J. Olby, Margaret E. Gruen, North Carolina State University; David M. Murdoch, Duke University Medical Center
Published: Apr. 15, 2022 in Journal of Alzheimer’s Disease
Background: Aging dogs suffer from canine cognitive dysfunction syndrome (CCDS), a condition in which cognitive decline is associated with amyloid pathology and cortical atrophy. Presumptive diagnosis is made through physical examination, exclusion of systemic/metabolic conditions, and completion of screening questionnaires by owners. Objective: This study aimed to determine whether cognitive function could be quantified in aging pet dogs, and to correlate cognitive testing with validated questionnaires and plasma neurofilament light chain (pNfL) concentration in aging dogs. Methods: Thirty-nine dogs from fifteen breeds were recruited (9.3 to 15.3 years). Owners completed the Canine Dementia Scale (CADES) and Canine Cognitive Dysfunction Rating scale (CCDR). Executive control and social cues were tested, and pNfL was measured with single molecule array assay. Comparisons were made between cognitive testing scores, CADES, CCDR scores, and pNfL. Results: CADES scoring classified five dogs as severe CCDS, six as moderate, ten as mild, and eighteen as normal. CCDR identified seven dogs at risk of CCDS and thirty-two as normal. Cognitive testing was possible in the majority of dogs, although severely affected dogs were unable to learn tasks. CADES score correlated with sustained attention duration (r=-0.47, p=0.002), inhibitory control (r=-0.51, p=0.002), detour (r=-0.43, p=0.001), and pNfL (r=0.41, p=0.025). Concentration of pNfL correlated with inhibitory control (r=-0.7, p=0.001). The CCDR scale correlated with performance on inhibitory control (r=-0.46, p=0.005). Conclusion: Our findings suggest that a multi-dimensional approach using a combination of questionnaires, specific cognitive tests, and pNfL concentration can be used to quantify cognitive decline in aging pet dogs.